Metastatic Melanoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

When cancerous cells from the primary tumor, also known as the original tumor, split off and travel to another site via the lymphatic or circulatory systems, a condition known as metastatic melanoma results. The condition is known as metastatic melanoma once it has spread, or metastasized. According to the SEER program, there may be 100,350 new cases of skin melanoma diagnosed in the United States in 2020. Approximately 100,000 new cases of melanoma are diagnosed in the US each year, and 7000 people die from metastases. Before it has a chance to metastasize, melanoma is best diagnosed and surgically treated when it is still small and thin. Metastatic melanoma still has a poor prognosis and survival rate in comparison to other cancers.

Description

When cancerous cells from the primary tumor, also known as the original tumor, break free and travel to another location via the lymphatic or circulatory systems, a condition known as metastatic melanoma develops. The condition is known as metastatic melanoma once it has spread or metastasized. This kind of melanoma typically progresses to stages 3 or 4. Melanoma often metastasizes to the lymph nodes, lungs, liver, bones, and brain, among other organs.

Metastatic Melanoma (Epidemiology)

According to the SEER program, there may be 100,350 new cases of skin melanoma diagnosed in the US in 2020. In the US, there are approximately 100,000 new cases of melanoma diagnosed each year, and 7000 people die from metastases. Melanoma incidence has increased quickly in comparison to other cancers, especially in White women. Melanoma has a variety of causes, including those that are genetic, immunological, and environmental. Immune system activation has received research attention due to the potential for developing precise targeted therapies. Melanoma predisposition is associated with the genetic disorder xeroderma pigmentosum (XP), which leads to inefficient repair of UV-induced DNA damage and a high mutation rate, and a number of genes, including CDKN2A, CDK4, and MC1R. Patients with metastatic MM have a poor prognosis, with a 5-year survival rate ranging from 5 to 19%, depending on the number and location of metastases. Diagnoses for metastases vary depending on the tissue. ranges from 10-60% in the skin, 10-40% in the lung, 5-35% in extra-regional lymph nodes, 5-35% in subcutaneous tissue, 2-20% in the central nervous system, 14-20% in the liver, 4-17% in the bone, 1-11% in the adrenal glands, 1-8% in the gastrointestinal tract, 5% in the pleura, 3% in the pancreas, and 1% in the heart, kidney, thyroid, and uterus.

Metastatic Melanoma-Current Market Size & Forecast Trends

The market for metastatic melanoma is projected to grow significantly, with estimates indicating an increase from approximately USD 3.9 billion in 2023 to around USD 8.9 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 7.93%. The global metastatic melanoma therapeutics market is expected to be valued at USD 7.12 billion in 2024, reaching approximately USD 15.8 billion by 2031, with a CAGR of 12.1% during this period. This growth is driven by the rising incidence of melanoma, advancements in targeted therapies and immunotherapies, and the increasing focus on innovative treatment strategies such as combination therapies and precision medicine. North America is anticipated to dominate the market due to high healthcare expenditure and advanced treatment facilities, while the Asia-Pacific region is expected to witness the highest growth rate, attributed to increasing awareness and healthcare investments. Overall, the metastatic melanoma market is well-positioned for substantial expansion through 2035, supported by ongoing research and development efforts aimed at improving patient outcomes.

When melanoma is still small and thin and before it has a chance to metastasize, it is best diagnosed and surgically treated. Metastatic melanoma still has a low chance of survival and a poor prognosis in comparison to other cancers. Metastatic melanoma responds less well to radiation therapy and traditional chemotherapy than other cancer types. For many years, immunotherapy research has been a focus because it involves using the body's immune system to combat the tumor. Numerous studies have also been conducted on immune system "stimulants" like interferon-alpha and interleukin-2. The various points along the biological pathways that fuel melanoma growth and spread are the targets of various newer drugs. Drugs that are currently being actively used or researched are those that are listed below. More should be accessible soon. Combinations of medications that target different elements of the melanoma growth and metastasis pathway are anticipated to have better results.

These medications include dabrafenib (Tafinlar), vemurafenib (Zelboraf), and nivolumab (Opdivo). They also improve the immune response to the tumor. All of these medicines have significant side effects, some of which are even life-threatening, to try and prevent the recurrence and spread of stage 3 tumors as well as stage 4 metastatic tumors that are no longer amenable to surgery.

Report Highlights

Metastatic Melanoma- Current Market Trends

Metastatic Melanoma- Current & Forecasted Cases across the G8 Countries

Metastatic Melanoma- Market Opportunities and Sales Potential for Agents

Metastatic Melanoma- Patient-based Market Forecast to 2035

Metastatic Melanoma- Untapped Business Opportunities

Metastatic Melanoma- Product Positioning Vis-a-vis Competitors' Products

Metastatic Melanoma- KOLs Insight